These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 34750764)

  • 21. The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction.
    Kjeldsen SE; Narkiewicz K; Burnier M; Oparil S
    Blood Press; 2019 Aug; 28(4):215-216. PubMed ID: 31184508
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
    Chrysant SG
    J Am Soc Hypertens; 2017 Jul; 11(7):461-468. PubMed ID: 28652105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sacubitril-valsartan: Hope or hype in the battle against cardiotoxicity due to cancer treatment?
    Yalta K; Gok M; Ozturk C; Yalta T
    Kardiol Pol; 2022; 80(9):958-959. PubMed ID: 35833474
    [No Abstract]   [Full Text] [Related]  

  • 24. Sacubitril-valsartan: Hope or hype in the battle against cardiotoxicity due to cancer treatment? Authors' reply.
    Sławiński G; Lewicka E
    Kardiol Pol; 2022; 80(9):960-961. PubMed ID: 35979643
    [No Abstract]   [Full Text] [Related]  

  • 25. [Clinical case: early connection of valsartan/sacubitril in the treatment of hypertension].
    Lozhkina NG; Spiridonov AN
    Kardiologiia; 2022 May; 62(5):72-74. PubMed ID: 35692177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Commentary to Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction.
    Buonacera A; Stancanelli B; Malatino L
    High Blood Press Cardiovasc Prev; 2021 Jul; 28(4):331-332. PubMed ID: 33905096
    [No Abstract]   [Full Text] [Related]  

  • 27. Examination of Initiation Patterns for Sacubitril/Valsartan Among Older Adults With HFrEF in the United States.
    Bhatt AS; Vaduganathan M; Lee SB; Desai RJ
    JACC Heart Fail; 2023 Aug; 11(8 Pt 1):1021-1023. PubMed ID: 37227387
    [No Abstract]   [Full Text] [Related]  

  • 28. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
    Jhund PS; McMurray JJ
    Heart; 2016 Sep; 102(17):1342-7. PubMed ID: 27207980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Making the Case for an Expanded Indication for Sacubitril/Valsartan in Heart Failure.
    Solomon SD; McMURRAY JJV
    J Card Fail; 2021 Jun; 27(6):693-695. PubMed ID: 33872760
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
    Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
    Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin-Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: You Win Some, You Lose Some.
    Ventura HO; Lavie CJ; Mehra MR
    J Am Coll Cardiol; 2023 Jul; 82(1):13-15. PubMed ID: 37220861
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction.
    Selvaraj S; Claggett BL; Packer M; Zannad F; Anand IS; Pieske B; Zhao Z; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
    J Am Heart Assoc; 2021 Sep; 10(17):e022069. PubMed ID: 33998278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Application of Sacubitril/Valsartan in Heart Failure: Erratum.
    Am J Ther; 2022 Nov-Dec 01; 29(6):e788. PubMed ID: 36608068
    [No Abstract]   [Full Text] [Related]  

  • 34. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
    N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan.
    Liu RC
    Am J Cardiovasc Drugs; 2018 Dec; 18(6):473-482. PubMed ID: 29850980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sacubitril/Valsartan: potential treatment for paediatric heart failure.
    Das BB; Scholl F; Vandale B; Chrisant M
    Cardiol Young; 2018 Sep; 28(9):1077-1081. PubMed ID: 29979147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
    Böhm M; Young R; Jhund PS; Solomon SD; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Packer M; McMurray JJV
    Eur Heart J; 2017 Apr; 38(15):1132-1143. PubMed ID: 28158398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic.
    Pogge EK; Davis LE
    Am J Cardiovasc Drugs; 2018 Apr; 18(2):143-151. PubMed ID: 29455335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sacubitril-Valsartan in Heart Failure: The Hard Sell of Spending More to Save Later.
    Samson R; Le Jemtel TH
    Am J Cardiol; 2023 Sep; 202():237-238. PubMed ID: 37495439
    [No Abstract]   [Full Text] [Related]  

  • 40. Angiotensin receptor-neprilysin inhibitors for hypertension-hemodynamic effects and relevance to hypertensive heart disease.
    Kario K; Williams B
    Hypertens Res; 2022 Jul; 45(7):1097-1110. PubMed ID: 35501475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.